%D9%83%D8%A7%D8%B1%D8%A8%D9%88%D8%A8%D9%84%D8%A7%D8%AA%D9%8A%D9%86%DA%A9%D8%B1%D8%A8%D9%88%D9%BE%D9%84%D8%A7%D8%AA%DB%8C%D9%86Category:CarboplatinCarboplatinCarboplatin%CE%9A%CE%B1%CF%81%CE%B2%CE%BF%CF%80%CE%BB%CE%B1%CF%84%CE%AF%CE%BD%CE%B7CarboplatinCarboplatino%DA%A9%D8%B1%D8%A8%D9%88%D9%BE%D9%84%D8%A7%D8%AA%DB%8C%D9%86KarboplatiiniCarboplatine%D4%BF%D5%A1%D6%80%D5%A2%D5%B8%D5%BA%D5%AC%D5%A1%D5%BF%D5%AB%D5%B6Carboplatino%E3%82%AB%E3%83%AB%E3%83%9C%E3%83%97%E3%83%A9%E3%83%81%E3%83%B3%E0%AC%95%E0%AC%BE%E0%AC%B0%E0%AD%8D%E0%AC%AC%E0%AD%8B%E0%AC%AA%E0%AD%8D%E0%AC%B2%E0%AC%BE%E0%AC%9F%E0%AC%BF%E0%AC%A8KarboplatynaCarboplatinaCarboplatin%C4%83%D0%9A%D0%B0%D1%80%D0%B1%D0%BE%D0%BF%D0%BB%D0%B0%D1%82%D0%B8%D0%BDKarboplatinKarboplatinKarboplatinKarboplatin%D0%9A%D0%B0%D1%80%D0%B1%D0%BE%D0%BF%D0%BB%D0%B0%D1%82%D0%B8%D0%BDCarboplatinQ415588%E5%8D%A1%E9%93%82
about
non-Hodgkin lymphomabreast cancerchoroid plexus carcinomainvasive mammary ductal carcinomasquamous cell carcinoma of the lungovarian cancerhead and neck cancerhead and neck squamous cell carcinomabrain cancerperitoneum cancerneuroendocrine carcinomaendometrial adenocarcinomaendometrial carcinomagerm cell cancercentral nervous system cancerlung benign neoplasmbronchus carcinomaovarian carcinomabone marrow diseaseembryonal cancerdiffuse large B-cell lymphomatongue squamous cell carcinomanon-small-cell lung carcinomaesophageal cancerbladder cancerosteosarcomaneuroblastoma, susceptibility tobone sarcoma
P2176
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsMolecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid TumorsStandard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell TumorsEvaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic AstrocytomaA Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerA Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or LymphomasA Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHNNeoadjuvant SHR-1210, or SHR-1210 in Combination With Pemetrexed and Carboplatin in Resectable NSCLCNab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast CancerAtezolizumab Trial in Endometrial Cancer - AtTEndAPX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction CancersComparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerAPatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLCStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By SurgeryCarboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerPhase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma MultiformeComparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaPhase I Study in Patients With Solid TumoursSorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerChemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant GliomasTreatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian CancerTrial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerCapecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic CancerFirst-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCInvestigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid TumorStudy of Abraxane and Carboplatin to Treat Small Cell Lung CancerStudy With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer PatientsDocetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian CancerGemcitabine + Carboplatin in Breast CancerPurged Circulating Tumor Cells (CTCs) From Metastatic Breast CancerPhase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLCCombination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid TumorsA Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to CisplatinA Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
P4844
Evoked-potential thresholds and cubic distortion product otoacoustic emissions in the chinchilla following carboplatin treatment and noise exposureThe effectiveness of N-acetyl-L-cysteine (L-NAC) in the prevention of severe noise-induced hearing lossHealth hazard evaluation report: evaluation of chemotherapy drug exposure in an outpatient infusion centerAntibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotidesAbstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Purged Circulating Tumor Cells (CTCs) From Metastatic Breast CancerTopotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid TumorsPaclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the UterusTreatment of Tumors of the Choroid Plexus EpitheliumSublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)A Combination of Pazopanib and Carboplatin in Advanced Solid MalignanciesTAK228 With Carbo and Taxol in Advanced MalignanciesMatched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian CancerA Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)In-depth survey report: engineering control evaluation at veterinary hospital CIn-depth survey report: engineering control evaluation at veterinary hospital DIn-depth survey report: engineering control evaluation at veterinary hospital FIn-depth survey report: engineering control evaluation at veterinary hospital BIn-depth survey report: engineering control evaluation at veterinary hospital EIn-depth survey report: engineering control evaluation at veterinary hospital AIn-depth survey report: engineering control evaluation at veterinary hospital G
P921
Q1138590-4DFEA017-53E8-470C-B7C0-32AEE7E1F285Q128581-6F8C5C7C-01C9-4B93-8B8A-EC6BC43667B3Q1524940-9222D3F8-BE02-4E90-96A6-90C0A0A81120Q1671685-370E259C-7761-4996-B6FD-2EEC651C8E3DQ17148386-83F53E0D-CC9E-42B1-A64A-1F90013743DEQ172341-0B321FD8-F6D7-4137-944B-987A14135653Q1783924-1A1B46B8-E22D-4769-AE07-FECE0CB4980EQ18348812-E52E696B-DD37-4CC7-BF0E-D0BE91F36074Q18554460-17DBCF13-D69A-4333-B0C3-7696C84BA38CQ18554882-96B1B6F2-8D41-4AA1-86A0-6AEF20E5717CQ18554913-329EB677-214D-4A3A-A552-FCAD2DD6EC23Q18555221-634B0B5A-9277-4D9F-B868-2A3C0880057BQ18555222-90FA614B-2E56-4ABD-A3F1-17969946FB25Q18555254-992C48BA-F849-4FE6-9DC7-D13664C326ACQ18556002-5E6AD854-503B-48AC-ADF6-2C12151B95C5Q18556020-9EA486E1-9C4C-4339-85ED-653CF174C80CQ18556109-C12AA264-7E4E-402E-92A3-1FCF284B06C2Q18556145-21FF059B-C42F-4E6C-B409-262F5ABCB6C8Q18556569-CE5F7A02-2DF9-4D57-A927-0F34DCC44DA1Q18557394-E879F2E0-7289-45C7-BA21-09A665378C2DQ2626074-3F4B55B5-AD6D-475A-B255-17325C092A13Q28757362-687F0A79-98D5-462B-983F-5ECC97CF1963Q3658562-F61751ED-BBF8-4D5C-B726-F946353BFB6FQ372701-D60A65D6-ED4F-4F83-B21A-C6837673F149Q504775-BFBF345B-3A14-4552-A9CD-2CC574DCD821Q549534-30B153A2-CF93-4304-9AD5-F6DE4DC0D317Q55998694-37DC77F5-440D-493B-91A0-ED044CBA179CQ56014469-CC7A524C-905B-422C-A2A4-7F1714864241
P2176
Q61862152-31F23EE8-EB49-49A0-93EA-580F5C0626FEQ61862186-C25FD7F9-302A-4B73-BC44-F979422C3E08Q61864694-73740498-FB38-4081-8ACA-D06252A5D9E6Q61864809-C2FC18A1-8100-4AF1-B30E-642153100D23Q61864902-8DC88C54-C4A2-4269-906C-94A0A8E70651Q61894354-94319120-DB6A-462A-90C2-4AB00029B0CBQ61894366-D89ABB34-6F38-41A1-9EC6-7D895C196CADQ61894670-DA82F8E1-1BBF-4715-8A95-F9EC828B2A73Q61902358-350AFD15-0FA5-4DBD-8785-7C2E372246C0Q61907171-EFC1C532-E5D8-4F24-AFA5-DA56A51EC703Q61907500-168EF887-C12A-45B2-861F-CD8D0EA7E450Q61908748-6F2890B9-C9A5-48E4-98D6-AF8C814EC283Q61908849-97C0B1C9-6133-4370-B2D5-EF29D259321FQ61908879-46938769-F96C-40AD-AB78-56CA0AB9A4D8Q61908888-B9037A25-DFB0-4803-BFFF-06E32697A2AFQ61909207-7C3D85AB-1BDB-48F0-A965-20E443F14594Q61909717-73D4AF89-0793-4232-9120-3248FD221F9EQ61914323-CFF6DBA7-7DB6-49F9-9359-3196207A460CQ61914695-0E8F6F9B-2110-43FA-9C39-72E5AC3C6B1DQ61915400-166E6B10-CB40-4441-9AED-9E8B507D6BD6Q61915530-B6CDDC46-D2C2-4F67-B1AE-1EC1C44CCECBQ61917521-C6041670-56BA-491B-9998-46363D74A1BFQ61917727-F4801943-DD68-4DBE-BA25-311D3F00B940Q61917745-346AE10A-BD42-4D72-B977-4922964AD206Q61917869-9AC552DF-EEB9-4F28-A7CB-EDC8FC49D491Q61918032-5EFF3375-C561-40F8-9FAF-24CA371E2D78Q61918150-64D970E7-2C3C-48FD-A8C5-9B0FE8EDF07BQ61918432-D207016D-CFB6-43F2-9904-ED85773123A5Q61920564-92CC09BF-9D8D-4EBF-AED9-57AB6B957B2FQ61920698-7A315B8E-F036-4A5F-8957-83EB5CEACF7DQ61920724-51D21589-50E2-482F-93B5-2A7648B4C28EQ61920784-1CC08723-3329-409C-914D-27C49C5131F3Q61920831-FC173C79-A01F-4F6A-A032-6E736F350BAAQ61921042-CBE1C44B-64BA-4975-91AC-EDC7BC39AD23Q61921209-DD549380-F02C-42DB-8DEF-DF4AAD59AF03Q61921384-D5B55614-6921-4256-876B-C15DE68C3BE9Q61921422-93A27C0C-5E7A-48C9-855E-5A4BFE98D8FEQ61921571-9991B031-9C12-4DCD-8494-8DB713073689Q61921652-49C9326A-F482-4D98-8DA2-C5D0BB784AC0Q61921758-6820474E-9AE1-464A-BED3-A5FC8D3F465B
P4844
Q23910496-E0B164C5-DA97-429A-972F-FB358854FAB7Q23920434-625EE71A-F114-45A0-AF82-C2CD8A7DCC6CQ24977607-8AB39104-D66B-4E4F-AB80-1538689D1BC6Q28327203-00FCAD8B-9288-4395-B7F2-6FFA49BF2D5BQ53161373-976e9361-405b-a64a-4af8-143e46da7cb0Q61864809-C3A5D95D-C52A-4CF6-835E-76E056981F68Q61921209-F29C9AD6-DACD-4861-8184-AFBD8C8128DCQ61980211-379DF1A6-4D3C-474A-9EBA-4E658F4A1F0BQ61980265-FA17A343-E190-4AB6-B90A-36BAE55392ADQ61980387-AEF85B20-42D1-4A93-BB77-CA20588DE8B7Q63316163-F6323501-E1C6-4FE7-8EC1-87F55A867C45Q63318673-E3C4F780-67C2-4F17-9E89-B27FC561DEFCQ63404154-4697AD3F-AEB0-48BD-8BBC-7B900C5E171FQ63578114-32F0FFD6-0FEB-4EA2-8A5A-C4BD1777AA83Q63578200-4659E72C-158E-4912-A911-E7D380D33D43Q96593318-3A0EE010-44A6-4C8A-B32B-0E54FEABB9A2Q96593319-1D124E5E-0602-410C-ACEB-524174C55D12Q96593321-E2F5C0C7-66EB-4556-9C53-57F9F7E978EEQ96593322-E9FACEC7-6B5F-472F-BB0A-E66E287CD0DCQ96593323-3A4BB9C7-91D5-4923-A910-7B154F9C35BEQ96593344-4796C7AE-347B-48B2-AE4B-652AE78C82A0Q96593345-EF0F7902-1743-49B3-90F0-575AA5DFF20F
P921
description
Metall-organische chemische Verbindung, Medikament
@de
carboplatin
@mk
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Carboplatin
@de
Carboplatin
@nl
Carboplatin
@vi
Carboplatina
@pt
Carboplatino
@es
Carboplatino
@it
Carboplatină
@ro
Karboplatiini
@fi
Karboplatin
@sh
Karboplatin
@sl
type
label
Carboplatin
@de
Carboplatin
@nl
Carboplatin
@vi
Carboplatina
@pt
Carboplatino
@es
Carboplatino
@it
Carboplatină
@ro
Karboplatiini
@fi
Karboplatin
@sh
Karboplatin
@sl
altLabel
1-Cyclobutanedicarboxylato)diammineplatinum(ii)
@cy
1-cyclobutanedicarboxylato)platinum
@cy
1-cyclobutanedicarboxylato)platinum(II)
@cy
41575-94-4
@fr
C6H12N2O4Pt
@fr
C6H14N2O4Pt
@it
CBDCA
@cy
CBDCA
@en
CBDCA
@ja
Carboplatin
@el
prefLabel
Carboplatin
@de
Carboplatin
@nl
Carboplatin
@vi
Carboplatina
@pt
Carboplatino
@es
Carboplatino
@it
Carboplatină
@ro
Karboplatiini
@fi
Karboplatin
@sh
Karboplatin
@sl